Development of Neem and Tulsi Tablets for Cardiovascular Care

Cardiovascular diseases (CVDs) represent a leading cause of mortality world wide, accounting for nearly 17.9 million deaths annually (World Health Organization, 2024). They encompass a broad spectrum of disorders involving the heart and blood vessels such as coronary artery disease, hypertension, myocardial infarction, heart failure, and atherosclerosis.

1.1 Pathophysiology of Cardiovascular Diseases

Cardiovascular diseases are multifactorial in origin. The pathogenesis typically begins with endothelial injury triggered by hyperlipidaemia, hypertension, or toxins such as nicotine.

1.2 Need for Herbal Interventions in Cardiovascular Diseases

Despite major advances in pharmacological therapy—such as beta-blockers,ACE inhibitors, and statin conventional treatments are often associated with side effects and high costs.

1.3 Neem [Azadirachta indica] ;

Figure; 1.1 The Neem leaves.

Neem, belonging to the family Meliaceous, has been traditionally employed for its antimicrobial, anti-inflammatory, and antioxidant effects. The plant contains bioactive constituents like azadirachtin, imboiled, cardiovascular diseases (CVDs) such as hypertension, atherosclerosis, myocardial infarction, and stroke are the leading causes of morbidity and mortality worldwide. The search for safe, effective, and affordable natural remedies has turned scientific. Among various medicinal plants used in traditional systems of medicine, Neem (Azadirachta indica) and Tulsi (Ocimum sanctum) have gained considerable attention due to their broad spectrum of pharmacological activities. The global view is changing towards the development and therapeutic use of safer preparations from medicinal plants for controlling various diseases. Azadirachta indica A., Juss, locally famous as “Neem”, is a popular herb for its medicinal value in a wide range of diseases including cardiovascular disorders, such as, hypertension and cardiac arrhythmia [29,33,41].

Neem (Azadirachta indica)

   ↓  [Antioxidant, Anti-inflammatory, Lipid-lowering actions]

Tulsi (Ocimum sanctum)

   ↓  [Stress modulation, HDL enhancement, Vaso protection]

Combined Effect

   →  [Figure 1.3: Comparative mechanisms of Neem and Tulsi contributing to cardiovascular protection. Endothelial repair, Reduced atherogenesis, Cardio protection]a. Antihyperlipidemic Effects. [40,43,44].

1.4  Pharmacological activities of neem;[15,24,25]

Figure; 1.2 Different Action of Neem.

  

Figure; 1.3 The Plant and flower of Tulsi .

Figure; 1.4 Different action of Tulsi

Figure; 1.5 Neem and Tulsi combination

Figure; 1.6Mechanism of Neem and Tulsi Combination

Together, the combination of Neem and Tulsi offers synergistic protection to the cardio-   -vascular system. Neem’s hypolipidemic and endothelial-stabilizing effects comple -ment Tulsi’s antioxidant and adaptogenic actions. Their combined mechanism includes reduction of oxidative stress, normalization of lipid profile, suppression of inflammatory mediators, improvement of vascular relaxation, and prevention of thrombosis. This holistic interaction supports myocardial integrity, enhances blood flow, and reduces the overall risk of hypertension, atherosclerosis, and ischemic heart diseases. This combination, therefore, acts on both structural and functional aspects of cardiovascular physiology — improving heart muscle performance, vascular elasticity, and blood lipid balance

AIM OF THE STUDY

The primary aim of this study is to scientifically investigate, evaluate, and establish the potential combined cardioprotective effects of Azadirachta indica (Neem) and Ocimum sanctum (Tulsi), and to determine how their synergistic bioactive compounds contribute to the prevention and management of cardiovascular diseases. The study aims to integrate traditional Ayurvedic knowledge with modern scientific validation, thereby exploring Neem–Tulsi as a natural, safe, and holistic alternative or adjunct therapy in cardiovascular disease management.

Objectives of the Study

1. To evaluate the phytochemical profile of Neem and Tulsi

• To identify and quantify major bioactive constituents present in Neem and Tulsi extracts.
• To analyze the antioxidant, anti-inflammatory, and cardiotonic phytochemicals that may contribute to therapeutic activity

2. To assess the antioxidant potential of Neem, Tulsi, and their combined extract

• To evaluate free radical scavenging activity using standard assays (DPPH, FRAP, ABTS, etc.).
• To determine whether the combination demonstrates superior antioxidative activity compared to single-herb extracts.

3. To investigate the effect of Neem and Tulsi on lipid metabolism

• To analyze changes in total cholesterol, triglycerides, LDL, and HDL levels following administration of Neem, Tulsi, and combination therapy.
• To determine if the combined extract provides enhanced lipid-lowering effects, helping prevent atherosclerosis.
• To study the influence of these extracts on lipid peroxidation and plaque formation.

4. To evaluate anti-inflammatory effects relevant to cardiovascular protection

• To assess the impact of each extract on inflammatory biomarkers such as TNF-α, IL-6, and CRP.
• To determine whether the combined extract more effectively suppresses inflammatory pathways like NF-κB.
• To correlate anti-inflammatory responses with prevention of endothelial dysfunction.

5. To study the effect of Neem and Tulsi on blood pressure and vascular responses

• To observe the extracts’ influence on systolic and diastolic blood pressure.
• To examine their ability to promote vasodilation through modulation of nitric oxide levels.
• To  determine Overall Expected Outcome

The study aims to provide strong scientific evidence that combining Neem and Tulsi may offer superior cardioprotective benefits by reducing oxidative stress, lowering cholesterol and triglycerides, improving vascular function, relieving inflammation, and protecting myocardial tissues. The outcomes of the study will support the development of a safe, natural, and multi-targeted herbal strategy for preventing and managing cardiovascular diseases.

PLAN OF WORK

1. Identification of Research Problem

Cardiovascular diseases (CVDs) continue to be the leading cause of mortality globally. Synthetic drugs used for CVD management often cause adverse effects .Herbal medicines like Neem (Azadirachta indica) and Tulsi (Ocimum sanctum) have documented cardioprotective properties, but their combined therapeutic potential remains underexplored. This study aims to scientifically evaluate their synergistic benefits.

2. Establishing Objectives and Hypothesis

Objectives

A] To prepare extract(s) of Neem and Tulsi.

B] To develop a combined formulation.

C] To evaluate its cardioprotective, antioxidant, and lipid-lowering effects.

D] To compare individual vs. combined extracts.

E] To determine the safety and stability of the formulation.

Hypothesis

“The combined extract of Neem and Tulsi will exhibit synergistic cardioprotective activity superior to their individual effects.”

3. Collection and Authentication of Plant Materials

A] Collect fresh Neem and Tulsi leaves from a pollution-free area or botanical garden.

B] Clean, shade-dry, and pulverize the leaves to coarse powder.

C] Send samples to a botanist/herbarium centre for authentication.

D] Maintain herbarium sheets for thesis documentation.

4. Preparation of Extractsby using Soxhlet apparatus;

A. Extraction Process

Choose extraction method based on study design:

Aqueous extraction, Ethanolic extraction ,Hydroalcoholic extraction

Conduct extraction using: Soxhlet apparatus, Maceration, Hot percolation, Filter the extract through Whatman filter paper. Concentrate using rotary evaporator. Dry the extract and store in airtight containers at 4°C.

B. Determination of % Yield

Calculate extractive yield for both Neem and Tulsi.

5. Phytochemical Analysis

A. Qualitative Screening

Analyze for presence of:Alkaloids, Flavonoids, Tannins, Saponins, Terpenoids, Phenolics ,Glycosides.

B. Quantitative Tests

Total phenolic content (TPC) ,Total flavonoid content (TFC), Antioxidant capacity assays

This helps in correlating phytochemicals with cardioprotective effect.

6. Formulation Development For Tablets

Prepare a combination formulation in selected ratio (e.g., 1:1 Neem:Tulsi).

Select excipients such as: Binders, Diluents, Disintegrants, Lubricants, Glidants

Optimize: Flow properties of powder blend, Compression force, Tablet hardness and uniformity, prepare trial batches and select best formulation based on evaluation.

7. Evaluation of Developed Formulation

A. Pre-compression Parameters; Bulk density, tapped density, Angle of repose, Carr’s index, Hausner ratio.

B. Post-compression Parameters; Weight variation, Hardness, Thickness, Friability, Disintegration time, Dissolution profile, Drug content uniformity, Stability testing (30 days accelerated study).

MATERIALS AND METHODS

1. Collection, Selection, and Authentication of Plant Materials

The fresh leaves of Azadirachta indica (Neem) and Ocimum sanctum (Tulsi) were carefully collected during the early morning hours from a pesticide-free herbal garden, ensuring that the plant material used for extraction was physiologically mature, free from microbial contamination, and representative of high-quality phytochemical composition; following collection, the leaves were meticulously sorted to remove dust, diseased parts, and extraneous matter, after which they were thoroughly washed with clean water and allowed to drain under shade so that no moisture-induced microbial degradation could occur.

2. Preparation of Dried Hydro-Alcoholic Extracts

The authenticated coarse leaf powders of Neem and Tulsi were processed individually for extraction using 70% ethanol, a solvent selected because it offers an excellent balance of polarity, enabling the solubilization of a broad spectrum of active phytoconstituents including alkaloids, tannins, saponins, glycosides, flavonoids, and terpenoids; for each extraction batch, 100 g of plant powder was macerated with 1 L of 70% ethanol in an amber-colored glass container to minimize light-induced chemical degradation.

3. Fractionation of Extracts (If Required for Purification)

To enhance the purity and pharmacological selectivity of active compounds, the dried extracts were fractionated using a sequential solvent extraction technique involving n-hexane and chloroform; the dried extracts were dissolved in minimal ethanol, transferred to a separatory funnel, and shaken with n-hexane to extract non-polar constituents such as fatty acids, chlorophylls, and waxes; after phase separation.

4. Phytochemical Screening of Crude and Fractionated Extracts

The crude and fractionated extracts of Neem and Tulsi were subjected to a comprehensive phytochemical evaluation using established qualitative procedures to identify various classes of chemical constituents; tests such as Mayer’s, Wagner’s, and Dragendorff’s reagents were used for the detection of alkaloids, while Shinoda, alkaline reagent tests, and lead acetate tests were utilized for flavonoid identification; phenolic compounds were confirmed through ferric chloride testing.

5. Selection and Compatibility Assessment of Excipients

The excipients used in the tablet formulation—microcrystalline cellulose (MCC), lactose monohydrate, PVP K-30, croscarmellose sodium, talc, and magnesium stearate—were selected based on their GRAS (Generally Recognized As Safe) status, functional suitability, and proven compatibility with plant extracts; MCC and lactose were chosen as diluents due to their excellent flowability, compressibility, and chemical inertness toward herbal components.

6. Preparation of Granules via Wet Granulation Technique

A precise quantity of Neem extract (125 mg), Tulsi extract (125 mg), and selected excipients were passed through a 60-mesh sieve to achieve uniform particle size distribution before blending; the sieved powders were mixed thoroughly for 10–15 minutes to ensure homogeneity, forming the initial dry mix; simultaneously, a binder solution was prepared by dissolving 2–5% PVP K-30 in purified water until a clear, uniform solution was obtained.

7. Compression of Tablets

The prepared granules were compressed into 500 mg tablets using a single-punch tablet compression machine fitted with an appropriate punch size (typically 10 mm flat-faced); during compression, machine parameters such as compression force, dwell time, and turret speed were optimized to achieve tablets with ideal hardness (4–6 kg/cm²), minimal friability (<1%), and uniform thickness; in-process quality control checks were performed at regular intervals to monitor tablet weight variation, surface appearance, capping or lamination tendencies, hardness, thickness, and edge chipping, ensuring consistency throughout the batch and adherence to pharmacopeial standards.

8. Evaluation of Prepared Granules

Before tableting, the granules were evaluated for various pre-compression parameters such as bulk density, tapped density, angle of repose, Carr’s index, Hausner ratio, and moisture content, as these properties directly affect tablet machine performance, flow behavior, die filling uniformity, and final quality; favorable values indicated adequate flowability and compressibility, which are essential for producing tablets with minimal weight variation and consistent mechanical strength.

9. Post-Compression Evaluation of Tablets

The finished tablets underwent extensive post-compression quality evaluation including weight variation, hardness, thickness, friability, disintegration time, wetting time, and in-vitro dissolution testing; disintegration tests were carried out in a USP disintegration apparatus using distilled water maintained at 37 ± 0.5°C, simulating physiological conditions; dissolution studies were conducted using the USP Type II paddle apparatus to assess the release profile of active constituents from the tablets over a defined time interval.

10. Statistical Analysis

All experimental data obtained from pre-compression, post-compression, and phytochemical studies were statistically analyzed using appropriate software such as GraphPad Prism; results were expressed as mean ± standard deviation, and comparative analyses were performed using one-way ANOVA or t-tests.

CONCLUSION

Neem (Azadirachta indica) and Tulsi (Ocimum sanctum), which are adored in ancient Ayurvedic medicine, have shown promising pharmacological properties as natural treatments. Their broad range of therapeutic actions, including antibacterial, anti inflammatory, antioxidant, hepatoprotective, antidiabetic, and immunomodulatory properties, make them essential resources in current phytotherapy. Neem includes bioactive chemicals such azadirachtin, nimbin, and nimbidin, which help it fight bacteria, viruses, and fungal infections. Similarly, Tulsi contains eugenol, ursolic acid, and rosmarinic acid, which are known to have adaptogenic, cardioprotective, characteristics. and antistress Both herbs have showed promise in preclinical and clinical trials for treating chronic ailments such as diabetes, cardiovascular disease, and respiratory disorders. Their usage as complementary medicines may lessen reliance on synthetic pharmaceuticals. Similarly, Tulsi is known for its adaptogenic, antibacterial, antioxidant, hepatoprotective, and anti diabetic properties. Key phytochemicals such as eugenol, ursolic acid, and rosmarinic acid help it manage stress, metabolic disorders, respiratory ailments, and infections. Both herbs have minimal toxicity profiles and offer interesting alternatives or supplementary options to synthetic pharmaceuticals, particularly for designing safe, multi-targeted treatments. Their synergistic potential is being investigated in polyherbal formulations to improve medicinal outcomes. However, despite widespread traditional use and preliminary scientific evidence, more in depth research, including clinical trials and extract standardization, is required to ensure uniform dose, efficacy, and safety. Finally, Neem and Tulsi are significant therapeutic plants with solid pharmacological foundations and promising future use in evidence-based integrative healthcare systems. Further research could open up more targeted applications and assist their widespread acceptance in modern medicine.

REFERENCES

1. Wealth of India. CSIR, Publication and information directorate, New Delhi, 1991; VII: 79-89.
2. WHO Monogram on selected medicinal plants. Dr Xiaorui Zhang, Acting Coordinator, Traditional Medicine, Department of Essential Drugs and Medicines Policy, World Health Organization. Geneva, 2002; Vol 2: 206-216.
3. Mondal S, MirdhaBR, Mahapatra SC.The science behindsacredness of Tulsi  (Ocimum sanctum Linn).  Indian J Physio Pharmacol, 2009; 53: 291-302
4. Abdul Jabbar Shah, Anwarul-Hassan Gilani, Hashim Muhammad Hanif, Saeed Ahmad, Sana Khalid and Ishfaq A. Bukhari, 2014
5. Bhargava KP, Singh N. Antistress activity of Ocimum sanctum Lin. Indian J Med. Res, 1981; 73: 443-451.
6. Devi PU, Ganasoundari A. Radioprotective effect of leaf extract of Indian medicinal plant Ocimum sanctum. Indian J Exp Biol, 1995; 33:205-8.
7. Sharma M, Kishore K, Gupta SK, Joshi S, Arya DS. Cardioprotective potential of Ocimum sanctum in isoproterenol induced myocardial infarction in rats. Mol Cell Biochem, 2001; 225(9): 75-83.
8. Sood S, Narang D, Dinda, AK, Maulik SK. Chronic oral administration of Ocimum sanctum Linn. augments cardiac endogenous antioxidants and prevents isoproterenol-induced myocardial necrosis in rats. J Pharmac Pharmacol, 2005; 57: 127133.
9. Arya D S, Nandave M, Ojha S K, Kumari S, Joshi S, Mohanty I. Myocardial salvaging effects of Ocimum sanctum in experimental model of myocardial necrosis: a haemodynamic, biochemical and histoarchitectura Assess-ment. Current Science, 2006; 91: 10667-672.
10. Suanarunsawat T, Ayutthaya WD, Songsak T, Thirawarapan S, Poungshompoo S. Lipid-lowering and antioxidative activities of aqueous extracts of Ocimum sanctum L. leaves in rats fed with a high-cholesterol diet. Oxid Med Cell Longev, 2011; doi:10.1155/2011/962025.
11. Jones B, Kenward MG. Design and analysis of cross-over trials. 2nd Ed. Chapman & Hall/CRC. New York. US. 2003.
12. Singh S, Majumdar DK, Yadav MR. Chemical and pharmacological studies of Ocimum sanctum fixed oil. Indian J Exp Biol, 1996; 34: 1212-1215.
13. Rai V, Iyer U, Mani UV. Plant Food. Effect of Tulasi (Ocimum sanctum) leaf powder supplementation on blood sugar levels, serum lipids and tissue lipids in diabetic rats. Hum Nutri, 1997; 50:9-16.
14. Campbell, W.B., D. Gebremedhin, P.F. Pratt and D.R. Harder, 1996. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circul. Res., 78: 415-423.
15. Khosla P, Gupta A, Singh J. A study of cardiovascular effects of Azadirachta indica (neem) on isolated perfused heart preparations. Indian J Physiol Pharmacol. 2002 Apr;46(2):241-4. PMID: 12500501.
16. Gupta S, Mediratta PK, Singh S, Sharma KK, Shukla R. Antidiabetic, anti hypocholesterolaemia and antioxidant effect of Ocimum sanctum (Linn) seed oil. Indian J Exp Biol, 2006; 44: 300304.
17. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep. 2011; 13(6):544-52.
18. Saggini A, Anogeianaki A, Angelucci D, et al. Cholesterol and vitamins: revisited study. J Biol Regul Homeost Agents. 2011; 25(4):505-15.
19. Zong, H. Cao, and F. Wang, “Anticancer polysaccharides from natural resources: a review of recent research,” Carbohy drate Polymers, vol. 90, no. 4, pp. 1395–1410, 2012. 
20. T. Efferth and E. Koch, “Complex interactions between Phyto chemicals. The Multi-Target Therapeutic concept of Phytother apy,” Current Drug Targets,vol.12,no.1,pp.122–132,2011.
21. Schmutterer H (1990) Properties and potentials of natural pesticides from neem tree. Annual eview of Entomol 35:271–298.
22. Ajayi FA (2002) Formulation and promotion of neem—seed derived Biopesticides as alternative to persistent organic pollutants (POPs) for the control of vegetable crop pests. In: Ukwe CN, Folorunso AO, Ibe AC, Z Z, N.E.S NES, Sieghart L (eds) Sustainable industrial utilization of neem tree (Azadirachta indica) in Nigeria. UNIDO Regional Development Centre, Lagos, pp 83–90.
23. Arumugam, A., Agullo, P., Boopalan, T., Nandy, S., Lopez, R., Gutierrez, C., ... Rajkumar, L. (2014). Neem leaf extract inhibits mammarycarcino -genesis by altering cell pro liferation, apoptosis, and angiogenesis. Cancer Biology and Therapy, 15(1), https://doi.org/10.4161/cbt.26604. 26–34.
24. Sinha, K.C., S.S. Riar, R.S. Tiwary, A.K. Dhawan and J. Bardhan et al., 1984. Neem oil as a vaginal contraceptive. Indian J. Med. Res., 79: 131-136.
25. Tep-Areenan, P. and P. Sawasdee, 2011. The vasorelaxant effects of Anaxagorea luzonensis A. Grey in the rat Aorta. Int. J. Pharmacol., 7: 119-124.
26. Rupani, R., & Chavez, A. (2018). Medicinal plants with traditional use: Ethnobotany in the Indian subcontinent. Clinics in Dermatology, IJIRT183855 36(3),1016/j.clindermatol.2018.03.005.
27. Deng, Y.x., Cao, M., Shi, D.x., Yin, Z.q., Jia,R.y., Xu, J., … & Zhao, J. (2013). Toxicological evaluation of neem (Azadirachta indica) oil: Acute and subacute toxi city. Environmental Toxicology and Pharmacology, 35(2), 240–246.
28. Atal CK, Kapoor BM. Cultivation and utilization of medicinal plants (Eds. PID CSIR), 1989. 2. [11] Siddiqui HH. Safety of herbal drugs-an overview. Drugs News & Views 1993; 1(2): 710.
29. Khan, M., A.U. Khan and A. Gilani, 2014. Blood pressure lowering effect of Morus alba is mediated through Ca++ antagonist pathway. Int. J. Pharmacol., 10: 225-230.
30. Ocimum sanctum. The Indian home remedy. In: Current Medical Scene, March-April 1992 (Edited and published by S. Rajeshwari, Cipla Ltd., Bombay Central, Bombay).
31. Sen P. Therapeutic potentials of Tulsi : from experience to facts. Drugs News & Views 1993; 1(2): 15–21.
32. Ayurvedic Pharmacopeia of India, Government of India. 1(2), 131-132. Ali A. Textbook of Pharmacognosy. New Delhi, India: Publication and Information Directorate; 1993. 
33. Shah, A.J. and A.H. Gilani, 2011. Blood pressure lowering effect of the extract of aerial parts of Capparis aphylla is mediated through endothelium-dependent and independent mechanisms. Clin. Exp. Hypertens., 33: 470-477.
34. Kokate C, Purohit AP, Gokhale SB. Pharmacognosy. Maharashtra, India: Nirali Prakashan; 2010.
35. Bilton, J.N., H.B. Broughton, P.S. Jones, S.V. Ley, Z. Lidert, E.D. Morgan, H.S. Rzepa, R.N. Sheppard, A.M.Z. Slawin & D.J. Williams. 1987. An X-ray crystallographic, mass spectroscopic, and NMR study of the limonoid insect antifeedant azadirachtin and related derivatives. Tetrahedron 43: 2805-2815.
36. Rembold, H & R.S. Annadurai. 1993. Azadirachtin inhibits proliferation of Sf9 cells in monolayer culture. Z. Naturforsch. 48c: 495-499.
37. Sarkar A, Lavania SC, Pandey DN, Pant MC. Changes in the blood lipid profile after administration of Ocimum sanctum (Tulsi) leaves in the normal albino rabbits. Indian J Physiol Pharmacol. 1994;38(4):311-2.
38. Suanarunsawat T, Boonnak T, Na Ayutthaya WD, Thirawarapan S. Antihyperlipidemic and cardioprotective effects of Ocimum sanctum L. fixed oil in rats fed a high fat diet. J Basic Clin Physiol Pharmacol. 2010;21(4):387‐400.
39. Meghwani H, Prabhakar P, Mohammed SA. Beneficial Effect of Ocimumsanctum (Linn) against Monocrotaline-Induced Pulmonary Hypertension inRats. Medicines (Basel). 2018;5(2):34.
40. Sadana B, Hira CK 1997. Effect of income and season onthe nutrient intake of rural women in central plainzone and Kandi area of Punjab. Ind J Reol, 24: 66-74.